Nykredit A S Takes Position in Amgen Inc. $AMGN

Key Points

• Nykredit A S purchased 135,233 Amgen shares during the second quarter, valued at approximately $49.0 million. Institutional investors collectively own 76.5% of Amgen’s stock.
• Analyst sentiment remains mixed, with an overall “Hold” consensus and an average price target of $381.32; recent targets range from $384 to $450.
• Amgen exceeded quarterly expectations, reporting $6.29 in EPS and $10.05 billion in revenue, while maintaining a quarterly dividend of $2.52 per share, representing a 2.6% yield.

Nykredit A S purchased a new position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 135,233 shares of the medical research company's stock, valued at approximately $48,971,000.

A number of other institutional investors also recently added to or reduced their stakes in the business. BlackRock Inc. grew its stake in Amgen by 4.8% in the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company's stock valued at $17,874,974,000 after acquiring an additional 2,261,544 shares during the last quarter. State Street Corp lifted its holdings in Amgen by 4.4% in the 4th quarter. State Street Corp now owns 30,591,403 shares of the medical research company's stock valued at $10,012,872,000 after purchasing an additional 1,287,310 shares in the last quarter. Capital World Investors raised its position in shares of Amgen by 22.9% in the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company's stock valued at $7,560,249,000 after buying an additional 4,302,237 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Amgen by 7.8% during the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company's stock valued at $4,665,822,000 after buying an additional 1,035,779 shares during the period. Finally, Norges Bank purchased a new position in shares of Amgen during the fourth quarter valued at approximately $2,164,162,000. Hedge funds and other institutional investors own 76.50% of the company's stock.

Insider Transactions at Amgen

In related news, SVP Rachna Khosla sold 2,000 shares of the firm's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the transaction, the senior vice president directly owned 6,404 shares in the company, valued at $2,642,098.28. This trade represents a 23.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares of the company's stock, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 6,222 shares of company stock valued at $2,540,926 over the last quarter. Insiders own 0.85% of the company's stock.

Analyst Ratings Changes

Several research analysts have weighed in on AMGN shares. Canaccord Genuity Group boosted their price target on Amgen from $366.00 to $384.00 and gave the company a "hold" rating in a report on Wednesday, August 5th. BMO Capital Markets cut Amgen from an "outperform" rating to a "market perform" rating and set a $450.00 price objective on the stock. in a report on Tuesday, September 8th. Royal Bank Of Canada lifted their price objective on Amgen from $370.00 to $400.00 and gave the company an "outperform" rating in a research report on Wednesday, August 5th. Oppenheimer upped their target price on Amgen from $400.00 to $450.00 and gave the company an "outperform" rating in a research note on Wednesday, August 5th. Finally, Guggenheim upped their price objective on shares of Amgen from $343.00 to $388.00 and gave the company a "neutral" rating in a research note on Monday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $381.32.

Amgen Trading Up 1.5%

Shares of AMGN opened at $385.65 on Friday. Amgen Inc. has a one year low of $269.77 and a one year high of $447.03. The stock has a 50-day moving average price of $401.76 and a 200 day moving average price of $367.81. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. The company has a market capitalization of $208.49 billion, a P/E ratio of 23.97, a P/E/G ratio of 2.74 and a beta of 0.43.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.62 by $0.67. The company had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.Amgen's revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period in the previous year, the business earned $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Sell-side analysts forecast that Amgen Inc. will post 22.94 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were given a dividend of $2.52 per share. The ex-dividend date of this dividend was Friday, August 21st. This represents a $10.08 annualized dividend and a dividend yield of 2.6%. Amgen's dividend payout ratio (DPR) is presently 62.65%.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: UBS initiated or reiterated a Buy rating on Amgen, providing a positive signal about the company’s valuation and commercial outlook. Amgen (AMGN) Gets a Buy from UBS
• Positive Sentiment: An updated analyst model raised Amgen’s fair-value estimate to US$388.03 from US$371.93. Analysts cited strong commercial execution, although they remain divided over patent risks and the company’s development pipeline. Amgen Stock Sees Modest Fair Value Lift
• Positive Sentiment: Amgen’s recent trading-session performance surpassed market returns, suggesting continued investor support despite longer-term uncertainty. The company also recently reported earnings and revenue above analyst expectations, supporting its fundamental backdrop. Amgen Surpasses Market Returns
• Positive Sentiment: Amgen is advancing a Phase 3 trial of romiplostim with prednisone for first-line immune thrombocytopenia treatment. Success could expand the drug’s addressable market and add support to the pipeline. Amgen Targets First-Line ITP Market
• Neutral Sentiment: Barclays maintained a Hold rating, while Citi reaffirmed a Hold rating and a $405 price target. The ratings indicate that analysts see upside potential but believe near-term risks are broadly balanced. Barclays Sticks to Its Hold Rating
• Negative Sentiment: Bristol Myers Squibb and Ono Pharmaceutical sued Amgen to block its proposed Opdivo biosimilar, creating potential legal costs, launch delays and commercial uncertainty. BMS and Ono Sue Amgen
• Negative Sentiment: Novartis’ failed cholesterol-drug trial increases pressure on Amgen’s olpasiran program to prove that lowering lipoprotein(a) reduces cardiovascular events. A disappointing outcome could weigh on future growth expectations. Failed Cholesterol Drug Raises the Stakes

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and rare diseases. The company uses biologic research, genetics and other advanced technologies to develop treatments intended to address significant unmet medical needs.

Amgen's medicines include Enbrel for certain inflammatory diseases; Prolia and Evenity for bone-related conditions; Xgeva for complications associated with cancer and bone disease; Repatha for cardiovascular risk reduction; Otezla for inflammatory conditions; and Aimovig for migraine prevention.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.